Loading
A phase 2 trial of Gemcitabine and Anlotinib in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms is a phase 2 interventional study registered as NCT06767813 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 80 participants planned, started 2024-03-19 and due to reach its primary completion in 2026-11. Interventions recorded: TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection and Anlotinib capsules.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.